What is the appropriate naltrexone dosing for alcohol use disorder, including oral and extended‑release injectable forms, and associated contraindications?

Naltrexone Dosing for Alcohol Use Disorder

For alcohol use disorder, initiate oral naltrexone at 50 mg once daily, or use extended-release injectable naltrexone 380 mg intramuscularly every 4 weeks, both combined with psychosocial interventions. 1

Oral Naltrexone Dosing

Standard regimen:

• 50 mg once daily is the FDA-approved and evidence-based dose 1
• Treatment duration: typically 3-6 months, can extend to 12 months 2
• Alternative supervised dosing schedules (when compliance monitoring is needed):
  • 50 mg weekdays + 100 mg Saturday
  • 100 mg every other day
  • 150 mg every third day 1

Important caveat: Extended dosing intervals above 50 mg daily carry higher hepatotoxicity risk and reduced opioid blockade efficacy 1. Use only when supervised administration is necessary and benefits outweigh risks.

Extended-Release Injectable Naltrexone

Standard regimen:

• 380 mg intramuscularly every 28 days (monthly) 3, 4
• Provides continuous naltrexone exposure for 30+ days 5
• Avoids first-pass metabolism and daily adherence issues 5
• Treatment persistence is significantly higher than oral formulation (OR 1.94) 6

The 190 mg dose showed less robust efficacy (17% reduction in heavy drinking vs 25% for 380 mg) 7.

Pre-Treatment Requirements

Critical safety step: Patients must be opioid-free before initiating naltrexone to avoid precipitated withdrawal 1:

• Minimum 7-10 days opioid-free for short-acting opioids
• Up to 2 weeks for patients transitioning from buprenorphine or methadone 1
• Verify opioid-free status with urine drug screen
• Consider naloxone challenge test if occult opioid use suspected (0.2 mg IV initially, then 0.6 mg if no withdrawal; or 0.8 mg subcutaneous) 1

Do not initiate if:

• Active opioid use or positive urine screen
• Clinical signs of opioid withdrawal
• Current need for opioid analgesics 3

Contraindications and Precautions

Absolute contraindications:

• Current opioid dependence or use (including tramadol) 1
• Acute opioid withdrawal 1
• Need for opioid analgesics 3

Hepatotoxicity concerns - the critical nuance: Multiple guidelines state naltrexone is "not recommended" in alcoholic liver disease due to hepatotoxicity risk 2, 8, 2, 8. However, this concern is based on supratherapeutic doses 3. The 2020 AASLD guidance notes naltrexone has "not been studied" in advanced liver disease but doesn't absolutely contraindicate it 9. Recent evidence (2026) indicates naltrexone is safe even in severe alcohol-associated cirrhosis 10.

Practical approach to liver disease:

• Monitor liver function tests at baseline and every 3-6 months 3
• Avoid in acute hepatitis or acute-on-chronic liver failure (insufficient safety data) 10
• In compensated or decompensated cirrhosis, benefits may outweigh theoretical risks 10
• Consider acamprosate as alternative (no hepatic metabolism, renally excreted) 9, 2

Efficacy Data

Oral naltrexone 50 mg daily:

• Number needed to treat = 18 to prevent return to any drinking 11
• Number needed to treat = 11 to prevent return to heavy drinking 11
• 51% abstinence vs 23% placebo in controlled trials 4

Injectable naltrexone 380 mg monthly:

• 25% reduction in heavy drinking days vs placebo 7
• Reduces drinking days by approximately 5 days per month 11
• Superior treatment persistence compared to oral formulation 6

Combination with Psychosocial Treatment

Naltrexone is effective only as part of comprehensive treatment 4, 1:

• Combine with cognitive behavioral therapy, motivational enhancement therapy, or contingency management 12
• Psychosocial intervention enhances medication compliance 13
• Naltrexone alone without behavioral support has limited success 4

Common Pitfalls

1. Precipitated withdrawal: Most serious error is starting naltrexone in opioid-dependent patients. Always verify adequate opioid-free period 1

2. Hepatotoxicity overestimation: Historical concerns about liver toxicity were based on doses 5-10 times higher than the 50 mg therapeutic dose. At standard dosing, hepatotoxicity is rare 3, 10

3. Poor compliance with oral formulation: Consider injectable formulation for patients with adherence challenges 5, 6

4. Monotherapy approach: Naltrexone without psychosocial support has minimal benefit 4, 1

5. Inadequate monitoring: Failure to check baseline and periodic liver function tests 3

Comparison with Acamprosate

When naltrexone is contraindicated or not tolerated, acamprosate is an alternative:

• Dose: 666 mg three times daily (1,998 mg/day for ≥60 kg; reduce by one-third if <60 kg) 2
• Number needed to treat = 11 to prevent return to any drinking 11
• No hepatic metabolism - safe in liver disease 13, 9, 8
• Renally excreted - avoid in renal failure 9
• No reported hepatotoxicity 9